AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Accurate Wealth Management LLC

Accurate Wealth Management LLC grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,463 shares of the company’s stock after purchasing an additional 275 shares during the quarter. Accurate Wealth Management LLC’s holdings in AstraZeneca were worth $567,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. FMR LLC lifted its stake in shares of AstraZeneca by 1.1% during the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock worth $1,801,080,000 after purchasing an additional 258,477 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of AstraZeneca by 8.7% during the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Fisher Asset Management LLC lifted its stake in shares of AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after acquiring an additional 524,175 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after acquiring an additional 186,010 shares in the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after acquiring an additional 1,605,758 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on AZN. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 0.5 %

Shares of NASDAQ AZN opened at $65.68 on Thursday. The stock’s 50 day moving average price is $65.98 and its two-hundred day moving average price is $74.69. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock has a market capitalization of $203.65 billion, a P/E ratio of 31.43, a PEG ratio of 1.19 and a beta of 0.46. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.87 earnings per share. On average, analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.